HPV (Human Papillomavirus), HPVHR, GPHPVHRISH, ISHPVFAM16ISH, ISNEGHPVISH, ISDNAHPVISH, Surg Path HPV High Risk DNA ISH, Surg Path HPV DNA ISH
The probe set used in this human papillomavirus (HPV) DNA in situ hybridization (ISH) test cannot detect all potential HPV serotypes that are associated with oropharyngeal squamous cell carcinoma. If this test is negative, a more sensitive test, Human Papillomavirus (HPV) High Risk E6/E7 RNA In Situ Hybridization, could be performed and reported if clinically indicated but will not be billed separately.
Detection of human papillomavirus DNA from high-risk genotypes (16, 18, 31, 33, and 51)
A pathology/diagnostic report and brief history are required.
Age of a cut paraffin section can affect staining quality. Stability thresholds vary widely among published literature. Best practice is for paraffin sections to be cut within 6 weeks.
Persistent infections with high-risk human papillomavirus (HPV) genotypes (16, 18, 31, 33, and 51) are associated with cervical, vaginal, vulvar, and head and neck malignancies. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) have shown better disease-specific survival and overall survival when compared to HPV-negative cases of OPSCC.
This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative. If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.